Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances DOI Creative Commons
Jiahui Zhang, Jingyi Fan, Mariusz Skwarczyński

et al.

International Journal of Nanomedicine, Journal Year: 2022, Volume and Issue: Volume 17, P. 869 - 900

Published: Feb. 1, 2022

Abstract: Persistent infection with high-risk human papillomaviruses (HPVs), such as HPV-16 and HPV-18, can induce cervical cancer in humans. The disease carries high morbidity mortality among females worldwide. Inoculation prophylactic HPV vaccines, Gardasil ® or Cervarix , is the predominant method of preventing 6 to 26 years age. However, despite availability commercial no therapeutic vaccines eliminate existing infections have been approved. Peptide-based which form one most potent vaccine platforms, broadly investigated overcome this shortcoming. are especially effective inducing cellular immune responses eradicating tumor cells when combined nanoscale adjuvant particles delivery systems. This review summarizes progress development peptide-based nanovaccines against infection. Keywords: papillomavirus, cancer, nanovaccine

Language: Английский

mRNA vaccines for cancer immunotherapy DOI Creative Commons
Yashavantha L. Vishweshwaraiah, Nikolay V. Dokholyan

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Dec. 14, 2022

Immunotherapy has emerged as a breakthrough strategy in cancer treatment. mRNA vaccines are an attractive and powerful immunotherapeutic platform against because of their high potency, specificity, versatility, rapid large-scale development capability, low-cost manufacturing potential, safety. Recent technological advances vaccine design delivery have accelerated vaccines’ clinical application. In this review, we present various platforms with focus on nucleic acid vaccines. We discuss rational optimization strategies for development. highlight the available lipid nanoparticles (LNPs) based systems. Finally, limitations future challenges.

Language: Английский

Citations

97
Development of Peptide-Based Vaccines for Cancer DOI Creative Commons

Noraini Abd-Aziz,

Chit Laa Poh

Journal of Oncology, Journal Year: 2022, Volume and Issue: 2022, P. 1 - 17

Published: March 15, 2022

Peptides cancer vaccines are designed based on the epitope peptides that can elicit humoral and cellular immune responses targeting tumor-associated antigens (TAAs) or tumor-specific (TSAs). In order to develop a clinically safe more effective vaccine for future, several issues need be addressed, these include selection of optimal antigen targets, adjuvants, immunization regimens. Another emerging approach involves use personalized peptide-based neoantigens enhance antitumor response. Rationally combinatorial therapy is currently being investigated with chemotherapeutic drugs checkpoint inhibitor therapies improve efficacy. This review discusses an overview development vaccines, role delivery systems peptide as well potential anticancer strategies.

Language: Английский

Citations

96
Sequential Targeting Hybrid Nanovesicles Composed of Chimeric Antigen Receptor T-Cell-Derived Exosomes and Liposomes for Enhanced Cancer Immunochemotherapy DOI
Tianchuan Zhu, Zhenxing Chen, Guanmin Jiang

et al.

ACS Nano, Journal Year: 2023, Volume and Issue: 17(17), P. 16770 - 16786

Published: Aug. 25, 2023

Paclitaxel (PTX)-based chemotherapy remains the main approach to treating lung cancer but systemic toxicity limits its use. As chimeric antigen receptor-T (CAR-T) cell-derived exosomes contain tumor-targeted CARs and cytotoxic granules (granzyme B perforin), they are considered potential delivery vehicles for PTX. However, low drug-loading capacity hepatotropic properties of obstacles their application extrahepatic cancer. Here, a hybrid nanovesicle named Lip-CExo@PTX was designed immunochemotherapy by fusing derived from bispecific CAR-T cells targeting both mesothelin (MSLN) programmed death ligand-1 (PD-L1) with lung-targeted liposomes. Due lung-targeting ability liposomes, over 95% intravenously administered accumulated in tissue. In addition, help anti-MSLN single-chain variable fragment (scFv), PTX inside were further delivered into MSLN-positive tumors. Notably, anti-PD-L1 scFv on blocked PD-L1 tumors avoid T cell exhaustion promoted PTX-induced immunogenic death. Furthermore, prolonged survival time tumor-bearing mice CT-26 metastatic model. Therefore, may deliver tumor through sequential targeted enhance antitumor effects, providing promising strategy

Language: Английский

Citations

55
The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects DOI Creative Commons
Bowen Lu,

Jing Ming Lim,

Boyue Yu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 1, 2024

Vaccines have proven effective in the treatment and prevention of numerous diseases. However, traditional attenuated inactivated vaccines suffer from certain drawbacks such as complex preparation, limited efficacy, potential risks others. These limitations restrict their widespread use, especially face an increasingly diverse range With ongoing advancements genetic engineering vaccines, DNA emerged a highly promising approach both diseases acquired While several demonstrated substantial success animal models diseases, challenges need to be addressed before application human subjects. The primary obstacle lies absence optimal delivery system, which significantly hampers immunogenicity vaccines. We conduct comprehensive analysis current status by focusing on viral non-viral systems, they play crucial roles exploration novel provide evaluation strengths weaknesses based our critical assessment. Additionally, review summarizes most recent breakthroughs pre-clinical clinical studies, highlighting for further trials this rapidly evolving field.

Language: Английский

Citations

55
The future of cancer immunotherapy: DNA vaccines leading the way DOI Open Access

Aanshi J. Pandya,

Yesha Shah, Nirjari Kothari

et al.

Medical Oncology, Journal Year: 2023, Volume and Issue: 40(7)

Published: June 9, 2023

Language: Английский

Citations

45
A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists DOI Creative Commons
Jessalyn J. Baljon, Alexander J. Kwiatkowski, Hayden M. Pagendarm

et al.

ACS Nano, Journal Year: 2024, Volume and Issue: 18(9), P. 6845 - 6862

Published: Feb. 22, 2024

Immune checkpoint blockade (ICB) has revolutionized cancer treatment and led to complete durable responses, but only for a minority of patients. Resistance ICB can largely be attributed insufficient number and/or function antitumor CD8+ T cells in the tumor microenvironment. Neoantigen targeted vaccines activate expand cell repertoire, historically, clinical responses have been poor because immunity against peptide antigens is typically weak, resulting activation cytotoxic cells. Herein, we describe nanoparticle vaccine platform that overcome these barriers several ways. First, reproducibly formulated using scalable confined impingement jet mixing method coload variety physicochemically diverse multiple adjuvants into pH-responsive, vesicular nanoparticles are monodisperse less than 100 nm diameter. Using this approach, encapsulated synergistically acting adjuvants, cGAMP monophosphoryl lipid A (MPLA), nanocarrier induce robust tailored innate immune response increased antigen immunogenicity. We found incorporating both nanovaccine enhanced expression dendritic costimulatory markers, pro-inflammatory cytokine secretion, cross-presentation. Additionally, delivery lymph node accumulation uptake by draining node. Consequently, codelivery antigen, cGAMP, MPLA antigen-specific delayed growth mouse models. Finally, improved efficacy immunotherapy murine colon carcinoma model. This work establishes versatile neoantigens synergistic enhance vaccines.

Language: Английский

Citations

39
The Promise and Potential of Metal–Organic Frameworks and Covalent Organic Frameworks in Vaccine Nanotechnology DOI
Yalini H. Wijesundara, Thomas S. Howlett, Sneha Kumari

et al.

Chemical Reviews, Journal Year: 2024, Volume and Issue: 124(6), P. 3013 - 3036

Published: Feb. 26, 2024

The immune system's complexity and ongoing evolutionary struggle against deleterious pathogens underscore the value of vaccination technologies, which have been bolstering human immunity for over two centuries. Despite noteworthy advancements these 200 years, three areas remain recalcitrant to improvement owing environmental instability biomolecules used in vaccines─the challenges formulating them into controlled release systems, their need constant refrigeration avoid loss efficacy, requirement that they be delivered via needle gastrointestinal incompatibility. Nanotechnology, particularly metal–organic frameworks (MOFs) covalent organic (COFs), has emerged as a promising avenue confronting challenges, presenting new frontier vaccine development. Although materials widely explored context drug delivery, imaging, cancer immunotherapy, role immunology vaccine-related applications is recent yet rapidly developing field. This review seeks elucidate prospective use MOFs COFs biomaterial stabilization, eliminating necessity cold chains, enhancing antigen potency adjuvants, potentializing needle-free delivery vaccines. It provides an expansive critical viewpoint on this evolving field research emphasizes vital contribution chemists driving further advancements.

Language: Английский

Citations

28
Targeting aging and age-related diseases with vaccines DOI
R. H. Wu, Fei Sun, Weiqi Zhang

et al.

Nature Aging, Journal Year: 2024, Volume and Issue: 4(4), P. 464 - 482

Published: April 15, 2024

Language: Английский

Citations

27
Cancer vaccines: platforms and current progress DOI Creative Commons
Wanting Lei, Kexun Zhou,

Ye Lei

et al.

Molecular Biomedicine, Journal Year: 2025, Volume and Issue: 6(1)

Published: Jan. 10, 2025

Abstract Cancer vaccines, crucial in the immunotherapeutic landscape, are bifurcated into preventive and therapeutic types, both integral to combating oncogenesis. Preventive cancer like those against HPV HBV, reduce incidence of virus-associated cancers, while vaccines aim activate dendritic cells cytotoxic T lymphocytes for durable anti-tumor immunity. Recent advancements vaccine platforms, such as synthetic peptides, mRNA, DNA, cellular, nano-vaccines, have enhanced antigen presentation immune activation. Despite US Food Drug Administration approval several full potential remains unrealized due challenges selection, tumor-mediated immunosuppression, optimization delivery systems. This review provides a comprehensive analysis aims implications vaccine, innovative discovery neoantigens enhancing specificity, latest strides platforms. It also critically evaluates role adjuvants immunogenicity mitigating immunosuppressive tumor microenvironment. The further examines synergistic combining with other therapies, chemotherapy, radiotherapy, checkpoint inhibitors, improve outcomes. Overcoming barriers effective identification, microenvironments, adverse effects is critical advancing development. By addressing these challenges, can offer significant improvements patient outcomes broaden scope personalized immunotherapy.

Language: Английский

Citations

2
Breast Cancer Vaccines: Disappointing or Promising? DOI Creative Commons
Siyuan Zhu, Ke‐Da Yu

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Jan. 28, 2022

Breast cancer has become the most commonly diagnosed globally. The relapse and metastasis of breast remain a great challenge despite advances in chemotherapy, endocrine therapy, HER2 targeted therapy past decades. Innovative therapeutic strategies are still critically need. Cancer vaccine is an attractive option as it aims to induce durable immunologic response eradicate tumor cells. Different types vaccines have been evaluated clinical trials, but none led significant benefits. Despite disappointing results at present, new promise from latest study indicates possibility applying combination with anti-HER2 monoclonal antibodies or immune checkpoint blockade. This review summarizes principles mechanisms underlying vaccines, recapitulates type administration routes vaccine, reviews current relevant addresses potential reasons for setbacks future directions explore.

Language: Английский

Citations

67